Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 18.08% and Operating profit at -10.25% over the last 5 years
2
Flat results in Sep 25
3
With ROE of 10.03%, it has a expensive valuation with a 3.50 Price to Book Value
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 8,164 Million (Mid Cap)
35.00
NA
1.52%
-0.06
6.82%
2.46
Revenue and Profits:
Net Sales:
1,239 Million
(Quarterly Results - Mar 2026)
Net Profit:
103 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.53%
0%
-6.53%
6 Months
-7.19%
0%
-7.19%
1 Year
-20.89%
0%
-20.89%
2 Years
-30.31%
0%
-30.31%
3 Years
-37.72%
0%
-37.72%
4 Years
-6.22%
0%
-6.22%
5 Years
-51.47%
0%
-51.47%
Sinocare, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
18.08%
EBIT Growth (5y)
-10.25%
EBIT to Interest (avg)
9.23
Debt to EBITDA (avg)
0.13
Net Debt to Equity (avg)
-0.08
Sales to Capital Employed (avg)
1.01
Tax Ratio
11.49%
Dividend Payout Ratio
37.35%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.38%
ROE (avg)
8.26%
Valuation key factors
Factor
Value
P/E Ratio
35
Industry P/E
Price to Book Value
3.50
EV to EBIT
37.12
EV to EBITDA
23.12
EV to Capital Employed
3.46
EV to Sales
2.50
PEG Ratio
1.47
Dividend Yield
1.10%
ROCE (Latest)
9.31%
ROE (Latest)
10.03%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Sep'25
Change(%)
Net Sales
1,239.40
1,189.60
4.19%
Operating Profit (PBDIT) excl Other Income
115.90
-22.20
622.07%
Interest
9.20
10.60
-13.21%
Exceptional Items
0.30
0.60
-50.00%
Consolidate Net Profit
103.00
-29.30
451.54%
Operating Profit Margin (Excl OI)
93.50%
-18.60%
11.21%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 4.19% vs -2.66% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 451.54% vs -129.10% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
4,420.40
4,039.40
9.43%
Operating Profit (PBDIT) excl Other Income
610.10
547.60
11.41%
Interest
52.90
77.00
-31.30%
Exceptional Items
-53.40
-87.70
39.11%
Consolidate Net Profit
345.90
195.80
76.66%
Operating Profit Margin (Excl OI)
88.00%
83.30%
0.47%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 9.43% vs 2.67% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 76.66% vs -60.10% in Dec 2023
About Sinocare, Inc. 
Sinocare, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






